Reduced expression of NFE2L2 are associated with poor outcome in breast cancer (24), ovarian cancer, and prostate cancer (25), but with favorable prognosis in cervical cancer (26), adrenocortical carcinoma, and kidney renal clear cell carcinoma (25), highlighting the dual role of NFE2L2 in cancer. This evidence concerns the gene NFE2L2 and ovarian carcinoma.